Enhancements to FDA Draft AI Guidance
ACR® provided comments to the U.S. FDA regarding the draft guidance to address risk management approaches throughout the lifecycle of AI-enabled medical devices.
Read moreEnhancements to FDA Draft AI Guidance
ACR® provided comments to the U.S. FDA regarding the draft guidance to address risk management approaches throughout the lifecycle of AI-enabled medical devices.
Read moreACR Support in Congressional Testimony
ACR submitted congressional testimony in support of funding the National Institute of Health in federal fiscal year 2026.
Read moreCY2026 Medicare Advantage Final Rule
Read more